SpringWorks sells two rare tumors drugs in the US and has two precision oncology drugs in early-stage development.

The new facility will produce biologic drugs and Keytruda, becoming Merck's first in-house U.S. site to make the blockbuster ...

Merck unveiled encouraging Phase 3 KEYNOTE-689 trial results for KEYTRUDA at the AACR 2025 Meeting, sparking investor ...

The firm reported revenues of $15.53 billion and adjusted earnings per share of $2.22, surpassing consensus predictions of ...

(Reuters) -U.S. drugmaker Merck is investing $1 billion in a new Delaware plant to expand its domestic production as it prepares to deal with the looming impact from President Donald Trump's tariffs, ...

The biggest M&A activity of the year arrived in the form of Merck KGaA’s earlier-disclosed agreement to buy Springworks Therapeutics Inc. for $47 per share in cash, which represents an equity value of ...

After developing treatments for rare tumors, SpringWorks Therapeutics is taking a buyout offer from Germany-based Merck KGaA.

Health-care companies rose amid deal activity. Germany's Merck KGaA agreed to acquire U.S. biopharmaceutical company SpringWorks Therapeutics for around $3.9 billion, in a bid to expand its oncology ...

This collection of health news covers a range of topics including criticisms of EU drug price proposals, new agreements ...

Laurence Norman - profile from The Wall Street Journal. News, articles, biography and photos.

Merck KGaA plans to acquire SpringWorks Therapeutics, a Connecticut-based specialist in biopharmaceuticals for severe rare diseases and cancer ...

Merck has reportedly moved to strengthen its position in oncology and rare diseases with a $3.9 billion agreement to acquire ...